Review Article

Neuromuscular Junction Protection for the Potential Treatment of Amyotrophic Lateral Sclerosis

Dan Krakora,1 Corey Macrander,1 and Masatoshi Suzuki1, 2

1 Department of Comparative Biosciences, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA
2 The Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, Madison, WI 53705, USA

Correspondence should be addressed to Masatoshi Suzuki, msuzuki@svm.vetmed.wisc.edu

Received 25 April 2012; Revised 15 June 2012; Accepted 15 June 2012

Academic Editor: Kenneth Hensley

Copyright © 2012 Dan Krakora et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease characterized by the progressive degeneration of upper and lower motor neurons (MNs), leading to muscular atrophy and eventual respiratory failure. ALS research has primarily focused on mechanisms regarding MN cell death; however, degenerative processes in the skeletal muscle, particularly involving neuromuscular junctions (NMJs), are observed in the early stages of and throughout disease progression. Many mechanisms explaining NMJ degeneration have been proposed such as the disruption of anterograde/retrograde axonal transport, irregular cellular metabolism, and changes in muscle gene and protein expression. Neurotrophic factors, which are known to have neuroprotective and regenerative properties, have been intensely investigated for their therapeutic potential in both the preclinical and clinical setting. Additional research should focus on the potential of preserving NMJs in order to delay or prevent disease progression.

1. Introduction

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of both upper and lower motor neurons (MNs) [1–3]. ALS research has primarily focused on mechanisms regarding MN cell death; however, degenerative processes in the skeletal muscle, particularly involving neuromuscular junctions (NMJs), are observed in the early stages of and throughout disease progression [4, 5]. Many studies support a “dying-back” hypothesis in which distal NMJ degeneration precedes and causes proximal cell body death. This paper will describe the NMJ, ALS pathology and the “dying-back” hypothesis (Figure 1). Then, we will discuss growth factor treatments and current progress regarding them.

2. Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease characterized by the progressive degeneration of upper and lower MNs, leading to muscular atrophy and eventual respiratory failure [1–3]. Diagnoses occur most often between the ages of 40 and 60 and the disease is fatal within 5-6 years of clinical diagnosis. ALS is the most frequent adult-onset MN disease with a worldwide incidence rate of 1–3 new cases per 100,000 individuals. About 90% of ALS cases are sporadic and the remaining 10% of ALS cases are familial (FALS). In about 20% of FALS cases, the cause can be attributed to a mutation in the Cu2+/Zn2+ superoxide dismutase 1 (SOD1), a ubiquitously-expressed free-radical defense enzyme [6]. The mutations cause misfolding of this normally stable homodimeric protein [7]. Overexpressing the human SOD1 mutant in rodents results in a disease progression similar to that observed in ALS patients, providing a valuable model (SOD1G93A mice or rats) on which a great deal of ALS research has been based [8, 9]. Two other heritable mutations associated with protein mislocalization and aggregation have become important areas of research in ALS: the RNA-processing proteins fused in sarcoma (FUS) and TARDNA binding protein 43 (TDP-43) [10, 11].
Although the SOD1 mutation represents a relatively rare, inherited form of ALS, both inherited and sporadic forms of ALS exhibit the same clinical course and neuropathology. Therefore, SOD1\textsuperscript{G93A} rodent models are important tools with which to better understand and investigate potential therapeutic treatments for ALS.

The mechanism underlying MN death in ALS is still unknown. Multiple mechanisms account for the selective vulnerability of MNs, including abnormal astrocyte and microglial activation, reduced neurotrophic factor secretion, protein aggregations, mitochondrial malfunction, rupture in the axonal passage, destruction in calcium metabolism, changes in skeletal proteins, high levels of excitotoxicity by glutamate and oxidative damage [12–14]. It is widely accepted that ALS is caused by MN degeneration. However, NMJ degeneration precedes and may even directly cause MN loss.

3. The Neuromuscular Junction

The neuromuscular junction (NMJ) is the synapse where the axon terminal of a MN meets the motor endplate, the highly excitable region of muscle fiber plasma membrane responsible for initiating action potentials across the muscle’s surface, ultimately causing the muscle to contract. (Figure 2(a)). In vertebrates, the signal passes through the NMJ via the neurotransmitter acetylcholine. Terminal branches expand outward from the motor nerve and emerge from their myelin sheath at the muscle to form terminals. These terminals are filled with synaptic vesicles, mitochondria, and tubules from smooth endoplasmic reticula. Synaptic terminals permit the necessary communication between MNs and their target muscles for muscle contraction. The motor end plate is densely populated by nicotinic acetylcholine receptors. Glial cells, called terminal Schwann cells (TSCs), are also intimately associated with the nerve-muscle connection. TSCs are nonmyelinating Schwann cells that play important roles in the formation, function, maintenance, and repair of the NMJ [15]. In neuromuscular junction diseases such as myasthenia gravis, Lambert-Eaton syndrome, and myasthenic syndrome, normal conduction through the neuromuscular junction is disrupted [16].

4. Presymptomatic Degeneration of the NMJ

Recent studies suggest that distal degeneration in the skeletal muscle plays a key role in the progression of ALS. Several studies using SOD1\textsuperscript{G93A} mice have shown that NMJ degeneration occurs in the early stages of disease progression, long before MN loss [17]. Furthermore, distal axonopathy followed NMJ denervation, but preceded both neuronal degeneration and the onset of clinical symptoms (Figure 1) [18–21]. There is growing evidence suggesting that muscle weakness is not apparent until a large proportion of the motor units are lost [5]. The time differential between NMJ degeneration and muscle weakness is caused by remaining axonal reinnervation of the muscle. This process is able to compensate for denervation at first and no loss in muscle strength is observed. Eventually, reinnervation is not able to keep up with degeneration from the disease and muscle weakness becomes apparent [14, 15].

Presymptomatic NMJ degeneration is supported by a study that used longitudinal magnetic resonance imaging (MRI) of the same SOD1\textsuperscript{G93A} mice. Researchers discovered that the muscle volume in these animals was significantly reduced from as early as week 8 of life, 4 weeks prior to clinical onset [22]. Neuropathological analysis using SOD1\textsuperscript{G93A} mouse samples demonstrated a similar pattern of disease with prominent evidence of axonal degeneration only in muscle [23]. Furthermore, Hegedus et al. (2007) [24] applied electromyography to the SOD1\textsuperscript{G93A} mice and explored the time course of functional loss in motor units. They also explored whether or not a difference existed between the loss of function in fast and slow twitch muscle. A significant decline in the whole muscle contractile force occurred 50
Figure 2: Schematic detailing NMJ degeneration and treatment. (a) A healthy, functioning NMJ, including TSCs and Ach receptors, is a vital point of communication between MNs in the spinal cord and muscle. (b) In ALS, NMJs begin to degenerate due to a number of pathologies, including disrupted axonal transport and irregular mitochondrial metabolism. NMJ degeneration occurs long before MN degeneration in the spinal cord, preceding clinical symptoms. (c) Ex vivo delivery of GDNF to NMJ via hMSC-GDNF may help to rescue TSCs from degenerative processes, thereby, delaying or preventing degeneration of the NMJ as a whole.

5. Possible Mechanisms of NMJ Denervation

In the last few decades, many explanations regarding NMJ degeneration have been proposed. Here, we describe some of the main components of the “dying-back” hypothesis which have been demonstrated (Figure 2).

One circumstance that may contribute to NMJ degeneration is the accumulation of SOD1<sup>G93A</sup> proteins in neurons, which slows anterograde and retrograde axonal transport, resulting in insufficient maintenance of the distal axon [29, 30]. An increased expression of Sema3A, an axon guidance protein, was found in SOD1<sup>G93A</sup> mice. It is thought that Sema3A, secreted by the TSCs, may lead to the repulsion of motor axons away from the NMJ, resulting in denervation [5]. Nogo-A, a neurite outgrowth inhibitor that is overexpressed in the slow-twitch fibers of SOD1<sup>G93A</sup> mice, may contribute to NMJ degeneration [31]. Overexpression of the dynamin subunit of dynactin also inhibits retrograde transport and causes an α-MN degeneration progression similar to that observed in ALS [32]. Angiogenin (ANG), which is mainly implicated in angiogenesis, also has axonal guidance functions by regulating neurite extension and pathfinding. Mutations in ANG can inhibit neurite outgrowth and negatively affects MN survival [5]. The consequences of
these mutations highlight the importance of anterograde and retrograde transport in maintaining the functionality of MNs. Since the fine-tuning of axonal transport is crucial for the survival of motor neurons, the development of molecular-targeted therapies to maintain axonal transport would be a powerful strategy.

Recent work has also shown that abnormalities in muscle energy metabolism may play a role in initiating NMJ degeneration. Large MNs are susceptible in a caliber-specific order with the largest caliber axons being the most susceptible to degeneration in SOD1G93A mice and human patients [33, 34]. This is supported by the observation that MNs innervating fast-twitch muscle fibers, mainly composed of type IIB and IID/X muscle fibers, showed signs of degradation before MNs innervating slow-twitch type I and IIA fibers in SOD1G93A rodents. Fast-twitch fibers are often innervated by the larger caliber type II MNs and slow-twitch fibers are innervated by the smaller caliber type I MNs [24]. It is generally accepted that the MNs innervating fast motor units have the largest soma sizes, axon calibers, and innervation ratios [35]. It has been proposed that irregular muscle metabolism is the cause of caliber-specific degradation. SOD1G93A rodents experience an increased basal metabolic rate and subsequent weight loss due to decreased levels of cellular adenosine-5′-triphosphate (ATP) [36]. An increased basal metabolic rate in SOD1G93A rats has also been linked to elevated levels of mitochondrial uncoupling protein [37]. Since larger-caliber nerve fibers have the highest metabolic needs, they would be the most susceptible in irregular metabolic conditions [5].

Alterations in trophic factor expression in the skeletal muscle could influence the course of MN degeneration and NMJ denervation. Numerous studies support this idea and demonstrate that the expression of growth factors dramatically changes in the muscle of patients with ALS throughout the stages of the disease. Although increased GDNF mRNA expression was observed in muscle biopsies from ALS patients [38], the other study showed that GDNF mRNA was decreased in the postmortem muscles of ALS patients [39]. These observations imply that GDNF gene expression decreases considerably as the disease progresses. Similarly, decreased expression of insulin-like-growth factor-I (IGF-I) has been observed in the skeletal muscle of ALS patients [40].

Furthermore, TSCs may be intimately involved in the course of ALS pathology. TSCs cap the nerve terminal covering motor terminal branches and synaptic boutons. These cells play key roles in the maintenance of preterminal axon structure and function during development and in adult life [41]. TSCs dysfunction or loss could thus serve as a possible trigger for NMJ degeneration. We recently performed a longitudinal study using SOD1G93A rats to understand the ability of TSCs to protect neuromuscular connections and found that the number of TSCs was significantly reduced following disease progression in ALS rat muscle. Given the importance of TSCs in the maintenance and function of NMJs, further studies are necessary to understand the mediators of TSC plasticity. Then, suitable cellular and molecular targets can be identified for novel treatments for ALS and other neuromuscular diseases.

6. Upper MNs and “Dying-Back”

The connection between upper MN degeneration and the dying-back hypothesis is still uncertain. Some early studies suggest that cortical and lower MN degeneration occur independently and not as a transsynaptic phenomenon [42, 43]. Attarian et al. conducted two studies comparing the responses of motor units in ALS patients to transcranial magnetic stimulation and peripheral nerve stimulation [44, 45]. Although a positive correlation existed between cortical and spinal dysfunction at first, it eventually disappeared, again suggesting that upper and lower MN degeneration occur separately. Furthermore, it has been suggested that the disease starts at a focal point which involves both upper and lower MNs, but that each set of MNs is affected separately as the disease progresses [46]. Some studies even suggest a “dying-forward” hypothesis which places corticomotoneuron degeneration at the earlier stages of disease progression. Corticomotoneuron hyperexcitability, induced by glutamate, may drive the anterior horn cell into a metabolic deficit [47]. However, identifying corticospinal MN degeneration and corresponding subcerebral projection neurons more accurately can now be done with recently identified molecular markers and FluoroGold labeling. Only ~6,000 corticospinal and corticobulbar MNs exist per hemisphere in mice, intermixed with millions of other cortical pyramidal neurons in the same region and layer V of the motor cortex [48]. As the pathology and progression of upper and lower MN degeneration is better understood, we can refine our treatment target and rationale.

7. Possible Treatments Targeting Muscle: How Can We Prevent “Dying-Back”?

Mounting evidence for the “dying-back” hypothesis suggests that the survival of NMJs is imperative in hindering the progression of ALS. Therefore, therapeutic treatments aimed at preserving NMJs may be the most effective.

One therapeutic strategy following this model is the direct delivery of neurotrophic factors to skeletal muscle. Neurotrophic factors are intimately involved in the development and survival of neurons thereby supporting their candidacy as a therapeutic option for ALS. MNs are able to bind, internalize, and retrogradely transport growth factors from muscle in a receptor-dependent manner. Alternatively, injecting viral constructs encoding growth factors directly into the spinal cord avoids the need for retrograde transport of the protein from the muscle. Several growth factors such as GDNF, IGF-I, vascular endothelial growth factor (VEGF), ciliary neurotrophic factor (CNTF), and brain-derived growth factor (BDNF) have been evaluated in experimental models of ALS (for review see [49, 50]). In nearly all cases, these factors have had positive effects on both MN survival and function in SOD1G93A rodents [51–54].

GDNF is important in the branching of neurons at the NMJ and modulating synaptic plasticity [55]. The enhanced
expression of GDNF in the muscle of the SOD1<sup>G93A</sup> mice delays disease onset, improves locomotor performance, and increases lifespan [51–53, 56–58]. However, delivering GDNF directly to the MNs within the spinal cord had only modest effects on the survival of facial MNs and no effect on lumbar MN survival or function. This was observed even though high levels of GDNF were expressed directly around dying MNs [59]. In support of this study, another report used promoter-driven transgenic mice to overexpress GDNF locally in either the muscle or spinal cord of SOD1<sup>G93A</sup> animals. GDNF expression in the muscle was able to slow disease progression and onset, but expression in the spinal cord had no effect [60].

In previous years, we demonstrated that intramuscular GDNF delivery using stem cells helps preserve NMJs (Figure 2(c)) [61]. Human mesenchymal stem cells (hMSC) were genetically modified to release GDNF (hMSC-GDNF) and were transplanted into the limb muscles of presymptomatic SOD1<sup>G93A</sup> rats. These cells survived, released GDNF, and significantly affected innervation of NMJs in the transplanted muscle at 6 weeks post surgery. hMSC-GDNF transplanted rats also survived ~18 days longer than their control littermates when animals were kept until endpoint [61].

IGF-I has been known to play a key role in MN survival, axonal growth, and the maintenance of synaptic connections [62, 63]. This trophic factor is involved in muscle and nerve tissue anabolism and thus induces muscle hypertrophy and promotes neural survival. After intramuscular treatment with adeno-associated virus expressing IGF-I, it was shown that IGF-I can be retrogradely transported from muscle to the spinal cord and led to MN protection in the SOD1<sup>G93A</sup> mice [52]. This effect was further increased when physical exercise was associated with treatment [64]. Another study reported that muscle-restricted expression of IGF-I isoforms maintained muscle integrity, stabilized neuromuscular junctions, enhanced MN survival, delayed the onset of disease, and slowed disease progression in the SOD1<sup>G93A</sup> mice [65]. These studies reappraised the potential role of the skeletal muscle and IGF-I signaling as a target for treatment in ALS patients.

VEGF is another trophic factor that contributes to the pathogenesis of ALS and possibly applies to muscle-target treatments. In SOD1<sup>G93A</sup> mice, increased expression of VEGF by intramuscular viral injections prolongs their survival and enhances motor performance [7, 53]. Also, intracerebroventricular administration of VEGF in a rat model of ALS enhanced MN survival, while an intraperitoneal injection of VEGF led to the preservation of NMJs [66].

Despite the promising effects in preclinical studies, several growth factors, including BDNF, CNTF, and IGF-I, did not yield positive results in clinical trials for ALS patients [67]. However, the failure of these trials may be attributed to factors such as inappropriate delivery routes and doses which were validated in preclinical trials and may have affected the pharmacological concentration of growth factors in target tissues [68]. Therefore, the therapeutic benefits of these growth factors may need to be tested using the direct delivery into skeletal muscle.

NMJ degeneration may also be alleviated by controlling abnormally elevated energy metabolism which occurs in muscle. It has been suggested that hypermetabolism in skeletal muscle drives a chronic energy deficit in SOD1<sup>G93A</sup> mice which precedes amyotrophy and muscle denervation. SOD1<sup>G93A</sup> mice show a body weight deficit compared to wild type mice [33]. This body weight deficit was not due to decreased food intake, but rather to an increase in the basal metabolic rate. Energy metabolism, especially lipid metabolism, was strikingly altered in these animals. Furthermore, gene expression changes and increased muscle glucose uptake implicated the muscle as a site of excessive nutrient consumption in SOD1<sup>G93A</sup> mice. Interestingly, a high-fat diet used to increase energy levels was enough to prolong the life of SOD1<sup>G93A</sup> rats and reduce muscle degeneration, although this strategy might not work well for human ALS patients due to insulin resistance [37, 69].

If an altered metabolic rate in skeletal muscle is critical for NMJ degeneration, exercise would also be expected to benefit ALS patients. Recent studies using ALS mouse models have reported a life span increase in exercised animals [70, 71]. Therapeutic exercise is also feasible, tolerated, and safe for patients with ALS [72, 73]. Clinical trials of ALS patients have suggested that regular physical exercise may be neuroprotective, ameliorate symptoms, and improve functionality [74]. Interestingly, synergistic effects of IGF-I gene delivery and exercise have profound effects on survival function [64]. Therefore, it is possible that combining exercise and stem-cell- or viral-based growth factor delivery may provide a more powerful therapy.

8. Conclusion

ALS is emerging as a “multisystemic” disease in which structural, physiological, and metabolic alterations occur in different tissues and cell types such as MNs, glia, and muscle tissues. The degenerating processes may act synergistically to induce and exacerbate the disease. Recent studies have provided evidence supporting a “dying-back” hypothesis in which distal NMJ degeneration precedes proximal neuronal cell death. It has been proposed that NMJ degeneration is not initially noticeable due to reinnervation processes by remaining axons of the muscle fibers as part of a compensatory mechanism. Eventually, however this process cannot keep up with the disease progression and muscle weakness is observed. Growth factor delivery targeting the skeletal muscle has provided significant results in protecting NMJ innervations, increasing MN survival, and prolonging the survival period of rodent models of ALS. On the other hand, treatments to rescue MNs according to a “dying-forward” model of MN pathology in ALS have shown only limited success in SOD1<sup>G93A</sup> transgenic rodents as well as humans. Due to the accessibility of muscle tissue, it is much easier to directly deliver growth factors in muscle than in other tissues such as the spinal cord. Perhaps the most powerful approach will be to target both the spinal cord (i.e., cell body) and muscle (i.e., nerve terminals of MNs).
Authors’ Contribution
D. Krakora and C. Macrander contributed equally to this work.

Acknowledgments
This work was supported by Grants from the ALS Association, NIH/NINDS (R21NS06104 to M. Suzuki), the University of Wisconsin Foundation, and the Les Turner ALS Foundation. This project was supported in part by grant 9U54TR000021 to the UW ICTR from NCATS/NIH, and by funds from the UW Stem Cell and Regenerative Medicine Center Pilot Grant Program.

References
[1] R. H. Brown Jr., “Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice,” Cell, vol. 80, no. 5, pp. 687–692, 1995.
[2] S. Boillée, C. Vande Velde, and D. Cleveland, “ALS: a disease of motor neurons and their nonneuronal neighbors,” Neuron, vol. 52, no. 1, pp. 39–59, 2006.
[3] D. W. Cleveland and J. D. Rothstein, “From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS,” Nature Reviews Neuroscience, vol. 2, no. 11, pp. 806–819, 2001.
[4] L. Dupuis and J. P. Loeffler, “Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models,” Current Opinion in Pharmacology, vol. 9, no. 3, pp. 341–346, 2009.
[5] M. Dadon-Nachum, E. Melamed, and D. O. O, “Neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) are associated with familial amyotrophic lateral sclerosis,” Nature, vol. 362, pp. 59–62, 1993.
[6] C. Zheng, I. Nennesmo, B. Fadeel, and J. I. Henter, “Vascular endothelial growth factor promotes survival in a transgenic mouse model of ALS,” Annals of Neurology, vol. 56, no. 4, pp. 564–567, 2004.
[7] M. E. Gurney, “Transgenic-mouse model of amyotrophic lateral sclerosis,” New England Journal of Medicine, vol. 331, no. 25, pp. 1721–1722, 1994.
[8] D. S. Howland, J. Liu, Y. She et al., “Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS),” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1604–1609, 2002.
[9] C. Vance, B. Rogelj, T. Hortobágyi et al., “Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6,” Science, vol. 323, no. 5918, pp. 1208–1211, 2009.
[10] M. Neumann, D. M. Sampathu, L. K. Kwong et al., “Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis,” Science, vol. 314, no. 5796, pp. 130–133, 2006.
[11] L. I. Bruijn, T. M. Miller, and D. W. Cleveland, “Unraveling the mechanisms involved in motor neuron degeneration in ALS,” Annual Review of Neuroscience, vol. 27, pp. 723–749, 2004.
[12] E. V. Ilieva, V. Ayala, M. Jove et al., “Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis,” Brain, vol. 130, no. 12, pp. 3111–3123, 2007.
[13] N. Lev, D. Ickowicz, Y. Barhum, E. Melamed, and D. Ofen, “DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS,” Journal of Molecular Neuroscience, vol. 38, no. 2, pp. 94–102, 2009.
[14] Z. Feng and C. P. Ko, “The role of glial cells in the formation and maintenance of the neuromuscular junction,” Annals of the New York Academy of Sciences, vol. 1132, pp. 19–28, 2008.
[15] J. Finsterer, L. Papić, and M. Auer-Grumbach, “Motor neuron, nerve, and neuromuscular junction disease,” Current Opinion in Neurology, vol. 24, pp. 469–474, 2011.
[16] K. C. Kamming, A. Kaplan, and C. E. Henderson, “Motor neuron diversity in development and disease,” Annual Review of Neuroscience, vol. 33, pp. 409–440, 2010.
[17] L. R. Fischer, D. G. Culver, P. Tennant et al., “Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man,” Experimental Neurology, vol. 185, no. 2, pp. 232–240, 2004.
[18] K. J. Brooks, M. D. W. Hill, P. D. Hockings, and D. G. Reid, “MRI detects early hindlimb muscle atrophy in G93A superoxide dismutase-1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosis,” NMR in Biomedicine, vol. 17, no. 1, pp. 28–32, 2004.
[19] L. Conforti, R. Adalbert, and M. P. Coleman, “Neuronal death: where does the end begin?” Trends in Neurosciences, vol. 30, no. 4, pp. 159–166, 2007.
[20] T. M. Wishart, S. H. Parson, and T. H. Gillingwater, “Synaptic vulnerability in neurodegenerative disease,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 8, pp. 733–739, 2006.
[21] S. Marcuzzo, I. Zucca, A. Mastropietro et al., “Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: a longitudinal MRI study,” Experimental Neurology, vol. 231, no. 1, pp. 30–37, 2011.
[22] C. R. Hayworth and F. Gonzalez-Lima, “Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1G93A ALS mouse model,” Neuroscience, vol. 164, no. 3, pp. 975–985, 2009.
[23] J. Hegedus, C. T. Putman, and T. Gordon, “Time course of preferential motor unit loss in the SOD1G93A mouse model of amyotrophic lateral sclerosis,” Neurobiology of Disease, vol. 28, no. 2, pp. 154–164, 2007.
[24] G. Dobrowolsky, M. Aucello, E. Rizzuto et al., “Skeletal muscle is a primary target of SOD1G93A-mediated toxicity,” Cell Metabolism, vol. 8, no. 5, pp. 425–436, 2008.
[25] L. Dupuis and A. Echaniz-Laguna, “Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments,” Current Drug Targets, vol. 11, no. 10, pp. 1250–1261, 2010.
[26] M. Wong and L. J. Martin, “Skeletal muscle–reduced expression of human SOD1 causes motor neuron degeneration in transgenic mice,” Human Molecular Genetics, vol. 19, no. 11, Article ID ddq106, pp. 2302–2307, 2010.
[27] M. Suzuki, J. McHugh, C. Tork et al., “GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS,” PLoS ONE, vol. 2, no. 1, Article ID e689, 2007.
[28] B. Zhang, P. H. Tu, F. Abtahian, J. Q. Trojanowski, and V. M. Y. Lee, “Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation,” Journal of Cell Biology, vol. 139, no. 5, pp. 1307–1315, 1997.
[29] T. L. Williamson and D. W. Cleveland, “Slowing of axonal transport is a very early event in the toxicity of ALS-linked
SOD1 mutants to motor neurons,” Nature Neuroscience, vol. 2, no. 1, pp. 50–56, 1999.

[31] N. Jokic, J. L. Gonzalez De Aguilar, P. F. Pradat et al., “Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity,” Annals of Neurology, vol. 57, no. 4, pp. 553–556, 2005.

[32] B. H. LaMonte, K. E. Wallace, B. A. Holloway et al., “Disruption of dynemin/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration,” Neuron, vol. 34, no. 5, pp. 715–727, 2002.

[33] D. M. Feinberg, D. C. Preston, J. M. Shefner, and E. L. Logigian, “Amplitude-dependent slowing of conduction in amyotrophic lateral sclerosis and polyneuropathy,” Muscle & Nerve, vol. 22, pp. 937–940, 1999.

[34] C. Bendotti, N. Calvaresi, L. Chiveri et al., “Early vacuolization and mitochondrial damage in motor neurons of ALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity,” Journal of the Neurological Sciences, vol. 191, no. 1-2, pp. 25–33, 2001.

[35] T. Gordon, C. K. Thomas, J. B. Munson, and R. B. Stein, “The resilience of the size principle in the organization of motor unit properties in normal and reinnervated adult skeletal muscles,” Canadian Journal of Physiology and Pharmacology, vol. 82, no. 8-9, pp. 645–661, 2004.

[36] L. Dupuis, H. Oudart, F. René, J. L. Gonzalez De Aguilar, and J. P. Loeffler, “Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 11159–11164, 2004.

[37] L. Dupuis, I. L. Gonzalez de Aguilar, A. Echaniz-Laguna et al., “Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons,” PLoS ONE, vol. 4, no. 4, Article ID e5390, 2009.

[38] E. Grundström, H. Askmark, J. Lindeberg, I. Nygren, T. Ebenald, and S. M. Aquilonius, “Increased expression of glial cell line-derived neurotrophic factor mRNA in muscle biopsies from patients with amyotrophic lateral sclerosis,” Journal of the Neurological Sciences, vol. 162, no. 2, pp. 169–173, 1999.

[39] M. Yamamoto, G. Sobue, K. Yamamoto, S. Terao, and T. Mitsuma, “Expression of glial cell line-derived growth factor mRNA in the spinal cord and muscle in amyotrophic lateral sclerosis,” Neuroscience Letters, vol. 204, no. 1-2, pp. 117–120, 1996.

[40] C. Lunetta, M. Serafini, A. Prelle et al. et al., “Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients,” Muscle & Nerve, vol. 45, pp. 200–208, 2012.

[41] Z. Feng and C. P. Ko, “The role of glial cells in the formation and maintenance of the neuromuscular junction,” Annals of the New York Academy of Sciences, vol. 1132, pp. 19–28, 2008.

[42] J. A. Kiernan and A. J. Hudson, “Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis,” Brain, vol. 114, no. 2, pp. 843–853, 1991.

[43] R. Pamphlett, J. Kril, and Tien Ming Hng, “Motor neuron disease: a primary disorder of corticomotoneurons?” Muscle and Nerve, vol. 18, no. 3, pp. 314–318, 1995.

[44] S. Attarian, J. P. Vedel, J. Pouget, and A. Schmied, “Cortical versus spinal dysfunction in amyotrophic lateral sclerosis,” Muscle and Nerve, vol. 33, no. 5, pp. 677–690, 2006.

[45] S. Attarian, J. P. Vedel, J. Pouget, and A. Schmied, “Progression of cortical and spinal dysfunctions over time in amyotrophic lateral sclerosis,” Muscle and Nerve, vol. 37, no. 3, pp. 364–375, 2008.

[46] S. Körner, K. Kollevle, M. Fahlbush et al., “Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis,” Muscle and Nerve, vol. 43, no. 5, pp. 636–642, 2011.

[47] P. G. Ince, “Neuropathology,” in Amyotrophic Lateral Sclerosis, R. H. Brown, V. Meinerger, and M. Swash, Eds., pp. 83–112, Martin Dunitz, London, UK, 2000.

[48] P. H. Ozdinler, S. Benn, T. H. Yamamoto, M. Güzel, R. H. Brown, and J. D. Macklis, “Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G93A transgenic ALS mice,” Journal of Neuroscience, vol. 31, no. 11, pp. 4166–4177, 2011.

[49] E. Hedlund, M. P. Hefferan, M. Marsala, and O. Isacson, “Cell therapy and stem cells in animal models of motor neuron disorders,” European Journal of Neuroscience, vol. 26, no. 7, pp. 1721–1737, 2007.

[50] T. W. Gould and R. W. Oppenheim, “Motor neuron trophic factors: therapeutic use in ALS?” Brain Research Reviews, vol. 67, no. 1-2, pp. 1–39, 2011.

[51] G. Arcadi, R. A. Lewis, M. E. Shy et al., “Increased survival and function of SOD1 mice after Glial cell-derived neurotrophic factor gene therapy,” Human Gene Therapy, vol. 13, no. 9, pp. 1047–1059, 2002.

[52] B. K. Kaspar, J. Lładó, N. Sherkat, J. D. Rothstein, and E. H. Gage, “Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model,” Science, vol. 301, no. 5634, pp. 839–842, 2003.

[53] M. Azzouz, G. S. Ralph, E. Storkebaum et al., “VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model,” Nature, vol. 429, no. 6990, pp. 413–417, 2004.

[54] S. Pun, A. F. Santos, S. Saxena, L. Xu, and P. Caroni, “Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF,” Nature Neuroscience, vol. 9, no. 3, pp. 408–419, 2006.

[55] C. E. Henderson, H. S. Phillips, R. A. Pollock et al., “GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle,” Science, vol. 266, no. 5187, pp. 1062–1064, 1994.

[56] M. H. Mohajeri, D. A. Figlewicz, and M. C. Bohn, “Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis,” Human Gene Therapy, vol. 10, no. 11, pp. 1853–1866, 1999.

[57] L. J. Wang, Y. Y. Lu, S. I. Muramatsu et al., “Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis,” Journal of Neuroscience, vol. 22, no. 16, pp. 6920–6928, 2002.

[58] M. Moreno-Igoa, A. C. Calvo, J. Ciriza, M. J. Munoz, P. Zaragoza, and R. Osta, “Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse ALS model,” Restorative Neurology and Neuroscience, vol. 30, pp. 69–80, 2012.

[59] S. Guillot, M. Azzouz, N. Déglon, A. Zurn, and P. Aebischer, “Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1G93A transgenic ALS mice,” Neurobiology of Disease, vol. 16, no. 1, pp. 139–149, 2004.

[60] W. Li, D. Brakefield, Y. Pan, D. Hunter, T. M. Myckatyn, and A. Parsadanian, “Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse.
[61] M. Suzuki, J. McHugh, C. Tork et al., “Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS,” *Molecular Therapy*, vol. 16, no. 12, pp. 2002–2010, 2008.

[62] M. E. Lewis, N. T. Neff, P. C. Contreras et al., “Insulin-like growth factor-I: potential for treatment of motor neuronal disorders,” *Experimental Neurology*, vol. 124, no. 1, pp. 73–88, 1993.

[63] S. A. Sakowski, A. D. Schuyler, and E. L. Feldman, “Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis,” *Amyotrophic Lateral Sclerosis*, vol. 10, no. 2, pp. 63–73, 2009.

[64] B. K. Kaspar, L. M. Frost, L. Christian, P. Umapathi, and F. H. Gage, “Synergy of insulin-like growth factor-I and exercise in amyotrophic lateral sclerosis,” *Annals of Neurology*, vol. 57, no. 5, pp. 649–655, 2005.

[65] G. Dobrowolny, C. Giacinti, L. Pelosi et al., “Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model,” *Journal of Cell Biology*, vol. 168, no. 2, pp. 193–199, 2005.

[66] E. Storkebaum, D. Lambrechts, M. Dewerchin et al., “Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS,” *Nature Neuroscience*, vol. 8, no. 1, pp. 85–92, 2005.

[67] A. Henriques, C. Pitzer, and A. Schneider, “Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?” *Frontiers in Neuroscience*, vol. 4, article 32, 2010.

[68] N. Lechtzin, J. Rothstein, L. Clawson, G. B. Diette, and C. M. Wiener, “Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment,” *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, vol. 3, no. 1, pp. 5–13, 2002.

[69] P. F. Pradat, G. Bruneteau, P. H. Gordon et al., “Impaired glucose tolerance in patients with amyotrophic lateral sclerosis,” *Amyotrophic Lateral Sclerosis*, vol. 11, no. 1-2, pp. 166–171, 2010.

[70] S. Deforges, J. Branchu, O. Biondi et al., “Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis,” *Journal of Physiology*, vol. 587, no. 14, pp. 3561–3572, 2009.

[71] I. Carreras, S. Yuarker, N. Aytan et al., “Moderate exercise delays the motor performance decline in a transgenic model of ALS,” *Brain Research*, vol. 1313, pp. 192–201, 2010.

[72] A. Chen, J. Montes, and H. Mitsumoto, “The role of exercise in amyotrophic lateral sclerosis,” *Physical Medicine and Rehabilitation Clinics of North America*, vol. 19, no. 3, pp. 545–557, 2008.

[73] V. Dalbello-Haas, J. M. Florence, and L. S. Krivickas, “Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease,” *Cochrane Database of Systematic Reviews*, no. 2, Article ID CD005229, 2008.

[74] M. Sanjak, E. Braver, W. L. Bockenek, H. J. Norton, and B. R. Brooks, “Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study,” *Archives of Physical Medicine and Rehabilitation*, vol. 91, no. 12, pp. 1920–1929, 2010.